|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
US7393682B1
(en)
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
|
US6180134B1
(en)
*
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
|
US5540935A
(en)
*
|
1993-12-06 |
1996-07-30 |
Nof Corporation |
Reactive vesicle and functional substance-fixed vesicle
|
|
US6132764A
(en)
*
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
|
US5512294A
(en)
*
|
1994-08-05 |
1996-04-30 |
Li; King C. |
Targeted polymerized liposome contrast agents
|
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
US5885613A
(en)
*
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
US6673364B1
(en)
|
1995-06-07 |
2004-01-06 |
The University Of British Columbia |
Liposome having an exchangeable component
|
|
AU705644B2
(en)
*
|
1995-08-01 |
1999-05-27 |
Novartis Ag |
Liposomal oligonucleotide compositions
|
|
US5908624A
(en)
*
|
1996-06-27 |
1999-06-01 |
Albany Medical College |
Antigenic modulation of cells
|
|
US6245349B1
(en)
|
1996-02-23 |
2001-06-12 |
éLAN CORPORATION PLC |
Drug delivery compositions suitable for intravenous injection
|
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
|
EP0921139A4
(de)
|
1996-07-29 |
2001-07-18 |
Kazunori Kataoka |
Modifizierte polymere mit einem poly(2-hydroxyethyl(meth)acrylat)molekülteil
|
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
|
TW520297B
(en)
*
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
|
US6056973A
(en)
*
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
ES2125817B1
(es)
|
1997-01-20 |
2000-01-01 |
Consejo Superior Investigacion |
Obtencion de nuevos cristales liquidos polimeros capaces de interaccionar con liposomas.
|
|
US5827533A
(en)
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
|
DE19726186A1
(de)
*
|
1997-06-20 |
1998-12-24 |
Boehringer Ingelheim Int |
Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
US6197332B1
(en)
|
1997-08-13 |
2001-03-06 |
Chiron Corporation |
Lipid-conjugated polyamide compounds and related compositions and methods thereof
|
|
US6734171B1
(en)
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
|
US6083923A
(en)
*
|
1997-10-31 |
2000-07-04 |
Isis Pharmaceuticals Inc. |
Liposomal oligonucleotide compositions for modulating RAS gene expression
|
|
US6986902B1
(en)
*
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
|
US20030215421A1
(en)
*
|
1999-07-21 |
2003-11-20 |
Mcdonald John R. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
KR100679906B1
(ko)
*
|
1998-09-16 |
2007-02-07 |
알자 코포레이션 |
리포솜-엔트랩된 토포이소머라제 억제제
|
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
|
US6251927B1
(en)
|
1999-04-20 |
2001-06-26 |
Medinox, Inc. |
Methods for treatment of sickle cell anemia
|
|
CA2369595C
(en)
*
|
1999-04-23 |
2010-10-05 |
Alza Corporation |
Conjugate having a cleavable linkage for use in a liposome
|
|
US7238368B2
(en)
*
|
1999-04-23 |
2007-07-03 |
Alza Corporation |
Releasable linkage and compositions containing same
|
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
|
US7303760B2
(en)
*
|
1999-04-23 |
2007-12-04 |
Alza Corporation |
Method for treating multi-drug resistant tumors
|
|
DE69928778T2
(de)
*
|
1999-06-08 |
2006-07-06 |
Gentium S.P.A., Villa Guardia |
Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln
|
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
|
US20020064520A1
(en)
*
|
1999-08-19 |
2002-05-30 |
Yanina Rozenberg |
Targeted artificial gene delivery
|
|
US20040197390A1
(en)
*
|
2001-05-29 |
2004-10-07 |
Shi-Kun Huang |
Neutral-cationic lipid for systemic delivery of factor VIII gene
|
|
AU7868400A
(en)
|
1999-10-08 |
2001-04-23 |
Alza Corporation |
Neutral-cationic lipid for nucleic acid and drug delivery
|
|
AU2136501A
(en)
*
|
1999-12-10 |
2001-06-18 |
Celator Technologies Inc. |
Lipid carrier compositions with protected surface reactive functions
|
|
CA2395636A1
(en)
*
|
1999-12-30 |
2001-07-12 |
Novartis Ag |
Novel colloid synthetic vectors for gene therapy
|
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
|
US7230088B2
(en)
|
2001-07-03 |
2007-06-12 |
Mallinckrodt, Inc. |
Compounds for dual photodiagnosis and therapy
|
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
|
DE60110057T2
(de)
*
|
2000-01-28 |
2005-09-08 |
Alza Corp., Mountain View |
Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung
|
|
US20010042099A1
(en)
*
|
2000-02-02 |
2001-11-15 |
Doongo Technologies, Inc. |
Apparatus and methods for optimizing traffic volume in wireless email communications
|
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
|
EP1318827A4
(de)
*
|
2000-09-08 |
2005-09-14 |
Gryphon Therapeutics Inc |
Durch polymere veränderte synthetische proteine
|
|
US6669926B1
(en)
*
|
2000-10-16 |
2003-12-30 |
Mallinckrodt, Inc. |
Hydrophilic light absorbing indole compounds for determination of physiological function in critically ill patients
|
|
US6656451B1
(en)
*
|
2000-10-16 |
2003-12-02 |
Mallinckrodt, Inc. |
Indole compounds as novel dyes for organ function monitoring
|
|
US6673334B1
(en)
*
|
2000-10-16 |
2004-01-06 |
Mallinkcrodt, Inc. |
Light sensitive compounds for instant determination of organ function
|
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
|
DE60141533D1
(de)
|
2000-12-08 |
2010-04-22 |
Life Technologies Corp |
Ukleinsäuremolekülen unter verwendung multipler erkennungsstellen
|
|
US6897196B1
(en)
*
|
2001-02-07 |
2005-05-24 |
The Regents Of The University Of California |
pH sensitive lipids based on ortho ester linkers, composition and method
|
|
US20020142304A1
(en)
*
|
2001-03-09 |
2002-10-03 |
Anderson Daniel G. |
Uses and methods of making microarrays of polymeric biomaterials
|
|
HUP0400174A2
(en)
*
|
2001-06-01 |
2007-02-28 |
Astellas Pharma Europ B V |
Lipid-polymer-conjugates compositions
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
|
AU2002315393A1
(en)
|
2001-06-21 |
2003-01-08 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
|
DE60238143D1
(de)
|
2001-09-18 |
2010-12-09 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
|
NZ577565A
(en)
|
2001-10-09 |
2010-10-29 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
|
AU2002348163A1
(en)
*
|
2001-11-02 |
2003-05-19 |
Intradigm Corporation |
Therapeutic methods for nucleic acid delivery vehicles
|
|
WO2004033620A2
(en)
|
2001-11-02 |
2004-04-22 |
Insert Therapeutics, Inc. |
Methods and compositions for therapeutic use of rna interference
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
WO2003057160A2
(en)
|
2002-01-02 |
2003-07-17 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7635463B2
(en)
|
2002-02-27 |
2009-12-22 |
Pharmain Corporation |
Compositions for delivery of therapeutics and other materials
|
|
US20030170299A1
(en)
*
|
2002-02-27 |
2003-09-11 |
Lee Robert J. |
Therapeutic methods for acute myeloid leukemia
|
|
DE60335608D1
(de)
*
|
2002-02-27 |
2011-02-17 |
Pharmain Corp |
Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
|
|
US20050260259A1
(en)
*
|
2004-04-23 |
2005-11-24 |
Bolotin Elijah M |
Compositions for treatment with glucagon-like peptide, and methods of making and using the same
|
|
WO2003078650A2
(en)
*
|
2002-03-12 |
2003-09-25 |
The Johns Hopkins University |
Manganese ion regulation of reverse transcriptase activity and methods of modulating same
|
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
|
CA2479665C
(en)
*
|
2002-03-20 |
2011-08-30 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
|
AU2003220917A1
(en)
*
|
2002-03-29 |
2003-10-13 |
Daiichi Pharmaceutical Co., Ltd. |
Phospholipid derivative
|
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
|
WO2004004635A2
(en)
|
2002-07-02 |
2004-01-15 |
Board Of Regents, The University Of Texas System |
Radiolabeled compounds and liposomes and their methods of making and using the same
|
|
CN1694959B
(zh)
|
2002-09-13 |
2013-09-18 |
雷普利瑟公司 |
非序列互补的抗病毒寡核苷酸
|
|
EP1549767A4
(de)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation der expression von forkhead-box o1a
|
|
US7531604B2
(en)
*
|
2002-09-30 |
2009-05-12 |
Nof Corporation |
Phospholipid derivative
|
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
WO2004110345A2
(en)
*
|
2002-10-29 |
2004-12-23 |
Pharmacia Corporation |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
|
KR101301653B1
(ko)
*
|
2002-10-29 |
2013-08-30 |
트랜세이브, 인코포레이티드 |
항감염제의 지속적인 방출
|
|
CA2504929C
(en)
*
|
2002-11-05 |
2014-07-22 |
Charles Allerson |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
ES2420914T3
(es)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
|
EP2336318B1
(de)
|
2002-11-13 |
2013-04-24 |
Genzyme Corporation |
Antisense-modulation von apolipoprotein-b-expression
|
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
|
JP2006517917A
(ja)
*
|
2002-12-19 |
2006-08-03 |
アルザ・コーポレーシヨン |
血管新生性の組織増殖の治療方法
|
|
CA2511815A1
(en)
*
|
2002-12-26 |
2004-07-22 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
|
NZ541124A
(en)
*
|
2002-12-26 |
2008-08-29 |
Mountain View Pharmaceuticals |
Polymer conjugates of interferon-beta with enhanced biological potency
|
|
KR101007828B1
(ko)
*
|
2003-01-06 |
2011-01-13 |
니치유 가부시키가이샤 |
인지질 유도체 및 그의 제조방법
|
|
EP1587908A4
(de)
*
|
2003-01-09 |
2008-02-20 |
Invitrogen Corp |
Zelluläre zuführung und aktivierung von polypeptid-nukleinsäurekomplexen
|
|
ES2400033T3
(es)
|
2003-02-11 |
2013-04-05 |
Antisense Therapeutics Ltd |
Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina
|
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
AU2004218354B2
(en)
*
|
2003-03-05 |
2009-10-01 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
US20060104968A1
(en)
*
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
|
US7968115B2
(en)
|
2004-03-05 |
2011-06-28 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of cancer
|
|
WO2004083219A1
(ja)
*
|
2003-03-20 |
2004-09-30 |
Nof Corporation |
リン脂質誘導体
|
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
|
US20060198882A1
(en)
*
|
2003-03-21 |
2006-09-07 |
Yechezkel Barenholz |
Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
|
|
AU2004227847A1
(en)
|
2003-03-31 |
2004-10-21 |
Alza Corporation |
Lipid particles having asymmetric lipid coating and method of preparing same
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
WO2004093788A2
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
|
US20040247624A1
(en)
*
|
2003-06-05 |
2004-12-09 |
Unger Evan Charles |
Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
|
|
EP1636342A4
(de)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
Oligomere verbindungen zur verwendung bei der modulation von genen
|
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
ATE422880T1
(de)
*
|
2003-08-26 |
2009-03-15 |
Smithkline Beecham Corp |
Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
|
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
|
US7425544B2
(en)
|
2003-09-18 |
2008-09-16 |
Eli Lilly And Company |
Modulation of eIF4E expression
|
|
NZ546272A
(en)
|
2003-10-10 |
2009-05-31 |
Alchemia Oncology Pty Ltd |
The modulation of hyaluronan synthesis and degradation in the treatment of disease
|
|
US20050175683A1
(en)
*
|
2003-10-24 |
2005-08-11 |
Yuanpeng Zhang |
Preparation of lipid particles
|
|
WO2005041870A2
(en)
|
2003-10-24 |
2005-05-12 |
Ader Enterprises, Inc. |
Composition and method for the treatment of eye disease
|
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
|
US7915227B2
(en)
*
|
2003-11-14 |
2011-03-29 |
Het Nederlands Kanker Instituut |
Pharmaceutical formulations employing short-chain sphingolipids and their use
|
|
EP1689432B1
(de)
|
2003-11-17 |
2009-12-30 |
Genentech, Inc. |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
|
JP2007512355A
(ja)
|
2003-11-21 |
2007-05-17 |
アルザ コーポレイション |
開裂性のｐｅｇで表面修飾されたリポソーム−ｄｎａ複合体で媒介される遺伝子送達
|
|
JP2007520481A
(ja)
*
|
2004-01-15 |
2007-07-26 |
アルザ・コーポレーシヨン |
治療薬を送達するためのリポソーム組成物
|
|
WO2005071080A2
(en)
|
2004-01-20 |
2005-08-04 |
Isis Pharmaceuticals, Inc. |
Modulation of glucocorticoid receptor expression
|
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
|
US8784881B2
(en)
|
2004-03-05 |
2014-07-22 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of diseases
|
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
EP1735009A4
(de)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
Irna mittel targeting vegf
|
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
|
US7187286B2
(en)
|
2004-03-19 |
2007-03-06 |
Applera Corporation |
Methods and systems for using RFID in biological field
|
|
DK1730280T3
(en)
*
|
2004-03-26 |
2019-02-04 |
Curis Inc |
RNA interference modulators for hedgehog signaling and applications thereof
|
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
CA2562527A1
(en)
*
|
2004-04-21 |
2005-11-10 |
Alza Corporation |
Polymer conjugate releasable under mild thiolytic conditions
|
|
US20060019972A1
(en)
*
|
2004-04-27 |
2006-01-26 |
California Institute Of Technology |
Methods of treating cancer by inhibiting histone gene expression
|
|
KR101223366B1
(ko)
|
2004-05-03 |
2013-01-16 |
헤르메스 바이오사이언스, 인코포레이티드 |
약물 전달에 유용한 리포좀
|
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
|
CA2569419A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
CA2569036A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Balkrishen Bhat |
Chimeric gapped oligomeric compositions
|
|
WO2005123140A2
(en)
*
|
2004-06-08 |
2005-12-29 |
Alza Corporation |
Preparation of macromolecular conjugates by four-component condensation reaction
|
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
EP1793805A1
(de)
*
|
2004-09-09 |
2007-06-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomale formulierungen mit einem amphipatischen schwachbasen-artigen tempamin zur behandlung von neurodegenerativen erkrankungen
|
|
EP1793804A2
(de)
*
|
2004-09-09 |
2007-06-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Verwendung von liposomalen glucocorticoiden zur behandlung von entzündungszuständen
|
|
US7635754B2
(en)
*
|
2004-09-22 |
2009-12-22 |
Aerovance, Inc. |
Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
|
|
US8435948B2
(en)
|
2004-09-29 |
2013-05-07 |
Mount Sinai School Of Medicine Of New York University |
Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
|
|
US9315862B2
(en)
*
|
2004-10-05 |
2016-04-19 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
|
JP2008515929A
(ja)
*
|
2004-10-08 |
2008-05-15 |
アルザ コーポレイション |
脂質連結部分を予備形成した脂質集合体にマイクロ波を使用して挿入する方法
|
|
TW200612993A
(en)
*
|
2004-10-08 |
2006-05-01 |
Alza Corp |
Lipopolymer conjugates
|
|
US20060110441A1
(en)
*
|
2004-10-28 |
2006-05-25 |
Harry Wong |
Lyophilized liposome formulations and method
|
|
US20090285878A1
(en)
|
2004-11-05 |
2009-11-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal drug formulations
|
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
|
JP2008520560A
(ja)
*
|
2004-11-15 |
2008-06-19 |
イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム |
組合せ治療
|
|
WO2006069344A2
(en)
|
2004-12-22 |
2006-06-29 |
Rutgers, The State University Of New Jersey |
Controlled release hydrogels
|
|
WO2012050591A1
(en)
|
2010-10-15 |
2012-04-19 |
Rutgers, The State University Of New Jersey |
Hydrogel formulation for dermal and ocular delivery
|
|
US8664392B2
(en)
|
2004-12-23 |
2014-03-04 |
Medibeacon, LLC |
Pyrazine derivatives for bioconjugation
|
|
WO2006086667A2
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
CN101175769A
(zh)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
用于调控血管完整性的方法和组合物
|
|
EP1866414B9
(de)
|
2005-03-31 |
2012-10-03 |
Calando Pharmaceuticals, Inc. |
Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
|
|
US20060286657A1
(en)
*
|
2005-06-01 |
2006-12-21 |
Samuel Zalipsky |
Novel bioconjugation reactions for acylating polyethylene glycol reagents
|
|
US20070015701A1
(en)
*
|
2005-06-01 |
2007-01-18 |
Samuel Zalipsky |
Macromolecular conjugates of bone morphogenetic protein-7
|
|
EP2476756A1
(de)
|
2005-06-15 |
2012-07-18 |
Massachusetts Institute of Technology |
Aminhaltige Lipide und ihre Verwendungen
|
|
WO2007005754A2
(en)
*
|
2005-07-01 |
2007-01-11 |
Alza Corporation |
Liposomal delivery vehicle for hydrophobic drugs
|
|
US20070055199A1
(en)
|
2005-08-10 |
2007-03-08 |
Gilbert Scott J |
Drug delivery device for buccal and aural applications and other areas of the body difficult to access
|
|
EP1926489A2
(de)
*
|
2005-09-12 |
2008-06-04 |
Alza Corporation |
Liposome zur behandlung von mehrfach-myelomen
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
CA2627585A1
(en)
|
2005-11-01 |
2007-05-10 |
Alnylam Pharmaceuticals, Inc. |
Rnai inhibition of influenza virus replication
|
|
DE102005053066A1
(de)
|
2005-11-04 |
2007-05-10 |
Basf Ag |
Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
|
|
JP2009516710A
(ja)
|
2005-11-21 |
2009-04-23 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
|
|
EP3067047B1
(de)
|
2005-12-08 |
2022-04-20 |
Insmed Incorporated |
Antiinfektive zusammensetzungen auf lipidbasis zur behandlung von lungeninfekten
|
|
CN101365424A
(zh)
*
|
2005-12-08 |
2009-02-11 |
耶路撒冷希伯来大学伊森姆研究发展公司 |
通过超声辐射改变脂质体组成的方法
|
|
EP1962908A2
(de)
*
|
2005-12-09 |
2008-09-03 |
Basf Se |
Verwendung von polyvinyllactam-polyoxyalkylen-blockcopolymeren als solubilisatoren für in wasser schwerlösliche verbindungen
|
|
KR101872061B1
(ko)
|
2005-12-19 |
2018-06-27 |
파마인 코포레이션 |
치료제를 전달하기 위한 소수성 코어 담체 조성물, 이 조성물의 제조 방법 및 그 조성물의 이용 방법
|
|
EP2422819B1
(de)
|
2006-01-26 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzung und deren Verwendungen in Bezug auf Huntingtin
|
|
EP2001893A2
(de)
*
|
2006-03-02 |
2008-12-17 |
Mallinckrodt, Inc. |
Thiadiazolverbindungen und ihre verwendung in der lichttherapie
|
|
JP2009529533A
(ja)
*
|
2006-03-10 |
2009-08-20 |
マリンクロット インコーポレイテッド |
光活性の化合物および組成物、ならびにそれらの使用方法
|
|
EP2527354A1
(de)
|
2006-03-31 |
2012-11-28 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Eg5-Gens
|
|
US20090306349A1
(en)
*
|
2006-03-31 |
2009-12-10 |
Rampak Corp |
Binding partners with immunoglobulin domains modified to have extended half-life
|
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
|
MX2008014005A
(es)
*
|
2006-05-03 |
2009-01-27 |
Baltic Technology Dev Ltd |
Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
|
|
US20070264322A1
(en)
*
|
2006-05-10 |
2007-11-15 |
Huang Ken S |
Method for making liposomes conjugated with temperature-sensitive ligands
|
|
CA2652770A1
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
|
US20090209625A1
(en)
*
|
2006-05-23 |
2009-08-20 |
Sanjay Bhanot |
Modulation of chrebp expression
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
WO2007149269A2
(en)
|
2006-06-12 |
2007-12-27 |
Oncomethylome Sciences S.A. |
Methylation markers for early detection and prognosis of colon cancers
|
|
JP2009534396A
(ja)
|
2006-06-22 |
2009-09-24 |
マリンクロッド・インコーポレイテッド |
ピラジン誘導体および腎臓の監視におけるその使用
|
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
|
CA2600220C
(en)
*
|
2006-09-07 |
2014-12-09 |
Canadian Blood Services |
Surface cross-linked lipidic particles, methods of production and uses therefor
|
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
|
US8278415B2
(en)
|
2006-12-21 |
2012-10-02 |
Centocor, Inc. |
Dimeric high affinity EGFR constructs and uses thereof
|
|
US8536113B2
(en)
*
|
2006-12-21 |
2013-09-17 |
Janssen Biotech, Inc. |
EGFR binding peptides and uses thereof
|
|
WO2008079982A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Liposome composition for targeting egfr receptor
|
|
EP2118118B1
(de)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Vermittelte zelluläre verabreichung von lna-oligonukleotiden
|
|
US20100093836A1
(en)
|
2007-01-29 |
2010-04-15 |
Isis Pharmaceuticals, Inc |
Compounds and methods for modulating protein expression
|
|
ES2556380T3
(es)
|
2007-02-22 |
2016-01-15 |
Genentech, Inc. |
Procedimientos para detectar una enfermedad inflamatoria del intestino
|
|
AU2008232891B2
(en)
|
2007-03-29 |
2012-01-12 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the Ebola
|
|
WO2008137717A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
|
WO2008141278A1
(en)
*
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Method for preparing antibody conjugates
|
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
|
JP2010534730A
(ja)
*
|
2007-07-26 |
2010-11-11 |
ビーエーエスエフ ソシエタス・ヨーロピア |
溶液中でのグラフト重合により得られる、ポリエーテルに基づく固体形態のコポリマーの調製方法
|
|
US7960336B2
(en)
*
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
|
KR20100046185A
(ko)
*
|
2007-08-09 |
2010-05-06 |
다이이찌 산쿄 가부시키가이샤 |
데스 도메인 함유 수용체 발현 세포에 아포토시스를 유도하는 이뮤노리포솜
|
|
US8563527B2
(en)
*
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
|
CN101878229A
(zh)
|
2007-09-28 |
2010-11-03 |
巴塞尔大学医院 |
用于治疗癌症的免疫脂质体
|
|
EP2205741A2
(de)
|
2007-10-02 |
2010-07-14 |
Amgen Inc. |
ERHÖHUNG DES ERYTHROPOIETINSPIEGELS MITTELS VERWENDUNG VON MIT miRNA HYBRIDISIERBAREN NUKLEINSÄUREN UND VORLÄUFER DAVON
|
|
JP2011502502A
(ja)
*
|
2007-11-05 |
2011-01-27 |
バルティック テクロノジー デヴェロプメント，リミテッド |
核酸のハイブリッド形成における修飾塩基を含むオリゴヌクレオチドの使用
|
|
JP5530933B2
(ja)
|
2007-12-10 |
2014-06-25 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法
|
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
|
US20090176892A1
(en)
|
2008-01-09 |
2009-07-09 |
Pharmain Corporation |
Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
|
|
EA019531B1
(ru)
|
2008-03-05 |
2014-04-30 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ Eg5 И VEGF
|
|
EP2105145A1
(de)
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
|
|
BRPI0911332A2
(pt)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
composições e uso de inibidores de epas1
|
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
|
US20100003315A1
(en)
|
2008-07-02 |
2010-01-07 |
Willeford Kenneth L |
Method and Composition for the Treatment of Skin Conditions
|
|
KR101647334B1
(ko)
*
|
2008-07-10 |
2016-08-10 |
세리나 쎄라퓨틱스, 인코포레이티드 |
불활성 말단기를 가진 폴리옥사졸린, 보호된 개시기로부터 제조된 폴리옥사졸린 및 그와 관련된 화합물
|
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
|
US20110237646A1
(en)
*
|
2008-08-07 |
2011-09-29 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
|
AU2009275387B2
(en)
|
2008-08-25 |
2010-07-08 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
|
EP2331690B1
(de)
|
2008-09-02 |
2016-01-13 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression eines mutierten egfr-gens
|
|
CN108165548B
(zh)
|
2008-09-22 |
2022-10-14 |
菲奥医药公司 |
减小大小的自递送RNAi化合物
|
|
EP2334793B1
(de)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
|
|
JP2012505243A
(ja)
|
2008-10-09 |
2012-03-01 |
ノースイースタン・ユニバーシティ |
多機能の自己集合性高分子ナノシステム
|
|
IL302142B1
(en)
|
2008-10-20 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Compounds and methods for inhibiting transthyretin expression
|
|
WO2010053572A2
(en)
|
2008-11-07 |
2010-05-14 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
|
EP2370580B1
(de)
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
|
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
|
WO2010065787A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
|
JP5766126B2
(ja)
|
2009-02-12 |
2015-08-19 |
クルナ・インコーポレーテッド |
脳由来神経栄養因子（ｂｄｎｆ）関連疾病の、ｂｄｎｆに対する天然アンチセンス転写物の抑制による治療
|
|
CA2752239C
(en)
|
2009-02-12 |
2021-03-30 |
Opko Curna, Llc |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
|
EP2403946A4
(de)
|
2009-03-04 |
2012-11-14 |
|
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
|
|
EP2228059A1
(de)
|
2009-03-12 |
2010-09-15 |
Universitätsspital Basel |
Chemotherapeutische Zusammensetzung für die Krebsbehandlung
|
|
US20100267806A1
(en)
|
2009-03-12 |
2010-10-21 |
David Bumcrot |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
|
CN102482677B
(zh)
|
2009-03-16 |
2017-10-17 |
库尔纳公司 |
通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
|
|
CN102549159B
(zh)
|
2009-03-17 |
2016-08-10 |
库尔纳公司 |
通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
|
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
|
DK2424987T3
(en)
|
2009-05-01 |
2018-02-26 |
Curna Inc |
TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG
|
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
|
WO2010129799A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
|
EP2432881B1
(de)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
|
|
WO2010135695A2
(en)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
|
ES2618576T3
(es)
|
2009-05-28 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
|
|
EP2440250A1
(de)
|
2009-06-11 |
2012-04-18 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Gezielt ausgerichtete liposome mit n-haltigen bisphosphonaten und ihre verwendung
|
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
|
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
|
EP2464336A4
(de)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
|
KR101892760B1
(ko)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
|
|
AU2010289400B2
(en)
|
2009-09-02 |
2014-10-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
EP4089169A1
(de)
|
2009-10-12 |
2022-11-16 |
Larry J. Smith |
Verfahren und zusammensetzungen zum modulieren der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
|
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
|
WO2011056234A1
(en)
|
2009-11-06 |
2011-05-12 |
Fibrogen, Inc. |
Treatment for radiation-induced disorders
|
|
CN102741294A
(zh)
|
2009-11-30 |
2012-10-17 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
|
AU2010326132B9
(en)
|
2009-12-01 |
2014-10-02 |
Translate Bio, Inc. |
Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
|
|
JP2013513588A
(ja)
|
2009-12-11 |
2013-04-22 |
ジーンコード エーエス |
Ｇｄｎｆファミリーリガンド（ｇｆｌ）のミメティックまたはｒｅｔシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法
|
|
NO2513310T3
(de)
|
2009-12-16 |
2018-03-31 |
|
|
|
US9068183B2
(en)
|
2009-12-23 |
2015-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
|
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
|
KR101853508B1
(ko)
|
2009-12-29 |
2018-06-20 |
큐알엔에이, 인크. |
종양 단백질 63 (ｐ63)에 대한 천연 안티센스 전사체의 억제에 의한 ｐ63에 관련된 질환의 치료
|
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
|
WO2011085347A2
(en)
|
2010-01-11 |
2011-07-14 |
Opko Curna, Llc |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
|
WO2011090971A2
(en)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
|
CN102782135A
(zh)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
|
|
EP2531175A2
(de)
|
2010-02-01 |
2012-12-12 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Liposomen mit amphipathischen wirkstoffen und herstellungsverfahren dafür
|
|
CA2790506A1
(en)
|
2010-02-22 |
2011-08-25 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
|
PE20130214A1
(es)
|
2010-02-23 |
2013-03-11 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
|
AU2011235276B2
(en)
|
2010-03-29 |
2015-09-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
|
|
TWI644675B
(zh)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
|
|
MX343559B
(es)
|
2010-04-29 |
2016-11-10 |
Ionis Pharmaceuticals Inc |
Modulacion de la expresion de transtiretina.
|
|
MX342239B
(es)
|
2010-05-03 |
2016-09-21 |
Genentech Inc * |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
|
CN107988228B
(zh)
|
2010-05-03 |
2022-01-25 |
库尔纳公司 |
通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
|
|
JP5866106B2
(ja)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
インスリンを産生し分泌する腸内分泌細胞の製造方法
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
DK2576783T3
(en)
|
2010-05-26 |
2018-03-12 |
Curna Inc |
TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
|
|
EP2576579B1
(de)
|
2010-06-02 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von leberfibrose
|
|
CN103080125A
(zh)
|
2010-07-02 |
2013-05-01 |
安吉奥开米公司 |
用于治疗性结合物的短且含d氨基酸的多肽及其使用
|
|
NO2593547T3
(de)
|
2010-07-14 |
2018-04-14 |
|
|
|
EP2609135A4
(de)
|
2010-08-26 |
2015-05-20 |
Massachusetts Inst Technology |
Poly(beta-amino-alkohole), ihre herstellung und verwendungen davon
|
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
RU2624048C2
(ru)
|
2010-10-06 |
2017-06-30 |
Курна, Инк. |
Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
|
|
JP6049623B2
(ja)
|
2010-10-22 |
2016-12-21 |
カッパーアールエヌエー，インコーポレイテッド |
α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
|
|
KR101913232B1
(ko)
|
2010-10-27 |
2018-10-30 |
큐알엔에이, 인크. |
인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
|
|
US20140134181A1
(en)
|
2010-11-05 |
2014-05-15 |
Kenneth E. Lipson |
Treatment Method For Lung Remodeling Diseases
|
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
US9518114B2
(en)
|
2010-11-12 |
2016-12-13 |
Purdue Research Foundation |
Treating bladder tumor cells using fibronectin attachment protein as a target
|
|
JP6071893B2
(ja)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー，インコーポレイテッド |
Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
|
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
CA2834968C
(en)
|
2011-01-05 |
2018-01-09 |
Livon Laboratories |
Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
|
|
WO2012104277A2
(en)
*
|
2011-01-31 |
2012-08-09 |
Nanobiotix |
Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
|
|
MX365647B
(es)
|
2011-02-02 |
2019-06-10 |
Excaliard Pharmaceuticals Inc |
El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
|
|
ES2634669T3
(es)
|
2011-02-08 |
2017-09-28 |
Halozyme, Inc. |
Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
|
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
|
CA2822021C
(en)
*
|
2011-03-02 |
2018-01-02 |
Sensulin, Llc |
Vesicle compositions
|
|
DK2691443T3
(da)
|
2011-03-28 |
2021-05-03 |
Massachusetts Inst Technology |
Konjugerede lipomerer og anvendelser af disse
|
|
KR102365961B1
(ko)
|
2011-03-29 |
2022-02-23 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
EP2508176A1
(de)
|
2011-04-08 |
2012-10-10 |
Lipotarg Gmbh |
Neues Kombinatonsbehandlung für Krebs
|
|
CN105886506A
(zh)
|
2011-04-13 |
2016-08-24 |
Isis制药公司 |
Ptp1b 表达的反义调节
|
|
DK2706988T3
(da)
|
2011-05-12 |
2020-01-20 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Liposomer omfattende polymer konjugerede lipider og relateret brug
|
|
EP3354343B1
(de)
|
2011-06-02 |
2023-09-06 |
President and Fellows of Harvard College |
Verfahren und verwendungen für ex-vivo-gewebekultursysteme
|
|
KR102128248B1
(ko)
|
2011-06-08 |
2020-07-01 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
|
CN103620036B
(zh)
|
2011-06-09 |
2016-12-21 |
库尔纳公司 |
通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
|
|
WO2012174476A2
(en)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
CA3191066A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
|
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
|
EP2723390B1
(de)
|
2011-06-23 |
2017-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
|
|
JP2014527036A
(ja)
|
2011-06-27 |
2014-10-09 |
ザ ジャクソン ラボラトリー |
癌および自己免疫疾患の処置のための方法および組成物
|
|
RS61235B1
(sr)
|
2011-07-13 |
2021-01-29 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Lipozomi koji ko-inkapsuliraju bisfosfonat i amfipatički agens
|
|
JP2014526887A
(ja)
|
2011-08-01 |
2014-10-09 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
造血幹細胞移植の成功率を改善する方法
|
|
KR101840512B1
(ko)
|
2011-09-20 |
2018-03-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Gcgr 발현의 안티센스 조절
|
|
EP2758074B1
(de)
|
2011-09-23 |
2020-04-22 |
Loma Linda University |
Bakterienstämme zur expression von methylasegenen und verwendungen davon
|
|
CN103796668B
(zh)
*
|
2011-09-28 |
2016-12-28 |
泰尔茂株式会社 |
含有血红蛋白的脂质体及其制造方法
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
WO2013063313A1
(en)
|
2011-10-25 |
2013-05-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gccr expression
|
|
PL2790682T3
(pl)
|
2011-12-16 |
2019-08-30 |
Nanobiotix |
Nanocząstki zawierające materiał metaliczny i materiał tlenku hafnu, ich wytwarzanie i zastosowanie
|
|
WO2013114377A1
(en)
|
2012-02-02 |
2013-08-08 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd |
Stable liposomes for drug delivery
|
|
ES2694592T3
(es)
|
2012-03-15 |
2018-12-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
CN104349783B
(zh)
|
2012-05-21 |
2018-07-13 |
英斯麦德公司 |
治疗肺部感染的系统
|
|
US20150267192A1
(en)
|
2012-06-08 |
2015-09-24 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
EP2882706A1
(de)
|
2012-08-13 |
2015-06-17 |
Massachusetts Institute of Technology |
Aminhaltige lipoide und ihre verwendungen
|
|
US20160136159A1
(en)
|
2012-09-17 |
2016-05-19 |
Chemedest Ltd. |
Method for Treating Peripheral Neuropathy
|
|
RU2675859C2
(ru)
|
2012-11-29 |
2018-12-25 |
Инсмед Инкорпорейтед |
Стабилизированные составы ванкомицина
|
|
CA2894846A1
(en)
|
2012-12-12 |
2014-06-19 |
Temple University - Of The Commonwealth System Of Higher Education |
Compositions and methods for treatment of cancer
|
|
AU2014203873A1
(en)
|
2013-01-07 |
2015-07-30 |
Biomedical Research Models, Inc. |
Therapeutic vaccines for treating herpes simplex virus type 2 infections
|
|
BR112015022868B1
(pt)
|
2013-03-14 |
2023-05-16 |
Ethris Gmbh |
Composições de mrna de cftr e usos e métodos relacionados
|
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
|
EP2968606B1
(de)
|
2013-03-15 |
2020-10-07 |
Loma Linda University |
Behandlung von autoimmunerkrankungen
|
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
|
EP2978446B1
(de)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antikörper zur behandlung von morbus alzheimer
|
|
WO2014179562A1
(en)
|
2013-05-01 |
2014-11-06 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
|
AR096203A1
(es)
|
2013-05-06 |
2015-12-16 |
Alnylam Pharmaceuticals Inc |
Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
|
|
ES2862125T3
(es)
|
2013-06-13 |
2021-10-07 |
Antisense Therapeutics Ltd |
Terapia combinada para acromegalia
|
|
US9827552B2
(en)
|
2013-07-17 |
2017-11-28 |
Clemson University |
Functionalized lipid modification of solid phase surfaces for use in chromatography
|
|
CA2922838A1
(en)
|
2013-09-05 |
2015-03-12 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
US10036020B2
(en)
|
2013-09-19 |
2018-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting JC virus (JCV)
|
|
US10077444B2
(en)
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
LT3052628T
(lt)
|
2013-10-04 |
2020-09-10 |
Alnylam Pharmaceuticals, Inc. |
Kompozicijos ir būdai alas1 geno raiškai nuslopinti
|
|
EP3060258A1
(de)
|
2013-10-22 |
2016-08-31 |
Shire Human Genetic Therapies, Inc. |
Mrna-therapie für phenylketonurie
|
|
PE20161242A1
(es)
|
2013-10-22 |
2016-12-11 |
Massachusetts Inst Technology |
Formulaciones de lipidos para la administracion de arn mensajero
|
|
EP3501605B1
(de)
|
2013-10-22 |
2023-06-28 |
Translate Bio, Inc. |
Mrna-therapie für argininosuccinat-synthase-mangel
|
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック， インコーポレイテッド |
平滑化変異体及びその使用方法
|
|
EP3134068B1
(de)
|
2014-04-21 |
2021-07-21 |
Heron Therapeutics, Inc. |
Abgabesysteme langzeitwirkender polymere
|
|
EP3509601A1
(de)
|
2014-04-21 |
2019-07-17 |
Heron Therapeutics, Inc. |
Pharmazeutische zusammensetzung mit einem abgabesystem, einem amidartigen lokalanesthetikum und meloxicam
|
|
AU2015249312B2
(en)
|
2014-04-25 |
2021-07-29 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
|
PT3142643T
(pt)
|
2014-05-15 |
2019-10-28 |
Insmed Inc |
Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
|
|
AU2015266764B2
(en)
|
2014-05-30 |
2019-11-07 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
WO2015200465A1
(en)
|
2014-06-24 |
2015-12-30 |
Shire Human Genetic Therapies, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
|
EP3160503B1
(de)
|
2014-06-26 |
2021-02-17 |
The Trustees of Columbia University in the City of New York |
Hemmung der serotoninexpression in enteroendokrinen darmzellenergebnissen bei der umwandlung in insulinpositive zellen
|
|
WO2016004202A1
(en)
|
2014-07-02 |
2016-01-07 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
|
EP3226889A4
(de)
|
2014-11-19 |
2018-11-21 |
The Trustees of Columbia University in the City of New York |
Osteocalcin zur behandlung von gebrechlichkeit im zusammenhang mit alterung
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
EP3234141A4
(de)
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir-tm-verbindungen
|
|
WO2016118476A1
(en)
|
2015-01-20 |
2016-07-28 |
The Children's Medical Center Corporation |
Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
|
|
CA2985330A1
(en)
|
2015-03-17 |
2016-09-22 |
Lipomedix Pharmaceuticals Ltd. |
Methods for the treatment of bladder cancer
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
CN107708668A
(zh)
|
2015-05-28 |
2018-02-16 |
纳米生物技术公司 |
用作治疗性疫苗的纳米粒子
|
|
MA50829A
(fr)
|
2015-06-01 |
2018-04-11 |
Sarepta Therapeutics Inc |
Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
|
|
WO2017004538A1
(en)
|
2015-07-02 |
2017-01-05 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
|
CA3205381A1
(en)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
|
WO2017027622A1
(en)
|
2015-08-11 |
2017-02-16 |
Scintillon Institute For Biomedical And Bioenergy Research |
Optical analyses of particles and vesicles
|
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
|
WO2017062835A2
(en)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
KR20180063255A
(ko)
|
2015-10-16 |
2018-06-11 |
입센 바이오팜 리미티드 |
캄프토테신 제약 조성물의 안정화
|
|
ES2938883T3
(es)
|
2015-11-05 |
2023-04-17 |
Los Angeles Childrens Hospital |
Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
|
|
AU2016352874B2
(en)
|
2015-11-10 |
2021-06-24 |
Children's Research Institute, Children's National Medical Center |
Echinomycin formulation, method of making and method of use thereof
|
|
MX2018012695A
(es)
|
2016-04-18 |
2019-06-20 |
Sarepta Therapeutics Inc |
Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido.
|
|
EP3585417B1
(de)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Methode der herstellung von codon-optimierter cftr-mrna
|
|
AU2018231832A1
(en)
|
2017-03-10 |
2019-08-08 |
Quiapeg Pharmaceuticals Ab |
Releasable conjugates
|
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
|
CA3063531A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
BR112019023650A2
(pt)
|
2017-07-06 |
2020-06-02 |
Arrowhead Pharmaceuticals, Inc. |
Agentes rnai para inibir a expressão de alfa-enac e métodos de uso
|
|
RU2020108580A
(ru)
|
2017-08-03 |
2021-09-03 |
Оцука Фармасьютикал Ко., Лтд. |
Лекарственное соединение и способы его очистки
|
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
|
US10722465B1
(en)
|
2017-12-08 |
2020-07-28 |
Quicksilber Scientific, Inc. |
Transparent colloidal vitamin supplement
|
|
JP7317026B2
(ja)
|
2018-01-30 |
2023-07-28 |
ライフ テクノロジーズ コーポレーション |
スマート分子分析システムのワークフローにおける使用のための機器、デバイス、および消耗品
|
|
KR20220127380A
(ko)
|
2018-03-09 |
2022-09-19 |
퀴아펙 파마슈티칼스 에이비 |
방출가능한 항체 접합체
|
|
US20210000936A1
(en)
|
2018-03-21 |
2021-01-07 |
Colorado State University Research Foundation |
Cancer vaccine compositions and methods of use thereof
|
|
EP3773505A4
(de)
|
2018-03-30 |
2021-12-22 |
Insmed Incorporated |
Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
|
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2020041793A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
WO2020053815A1
(en)
|
2018-09-12 |
2020-03-19 |
Quiapeg Pharmaceuticals Ab |
Releasable glp-1 conjugates
|
|
US20220024999A1
(en)
|
2018-11-29 |
2022-01-27 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating rna
|
|
EP3930763A1
(de)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Zusammensetzungen mit mesoporösen siliciumdioxidteilchen zur viralen verabreichung
|
|
US11291702B1
(en)
|
2019-04-15 |
2022-04-05 |
Quicksilver Scientific, Inc. |
Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
|
|
MX2022002689A
(es)
|
2019-09-03 |
2022-04-07 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
|
|
EP4038189A1
(de)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CA3170377A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
|
AU2021232062A1
(en)
|
2020-03-06 |
2022-09-29 |
Colorado State University Research Foundation |
Production of vaccines comprising inactivated SARS-CoV-2 viral particles
|
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
BR112022020145A2
(pt)
|
2020-04-06 |
2023-01-03 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciamento da expressão de myoc
|
|
WO2021207189A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
|
EP4199960A2
(de)
|
2020-08-21 |
2023-06-28 |
Novartis AG |
Zusammensetzungen und verfahren zur in-vivo-erzeugung von car-exprimierenden zellen
|
|
WO2022226291A1
(en)
|
2021-04-22 |
2022-10-27 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
WO2024026452A1
(en)
|
2022-07-29 |
2024-02-01 |
Repertoire Immune Medicines, Inc. |
T cell epitopes associated with type 1 diabetes
|
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|